Polymeric nanoparticles for targeted radiosensitization of prostate cancer cells

Jyothi U. Menon, Vasu Tumati, Jer Tsong Hsieh, Kytai T. Nguyen, Debabrata Saha

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

One of the many issues of using radiosensitizers in a clinical setting is timing daily radiation treatments to coincide with peak drug concentration in target tissue. To overcome this deficit, we have synthesized a novel nanoparticle (NP) system consisting of poly (lactic-co-glycolic acid) (PLGA) NPs conjugated with prostate cancer cell penetrating peptide-R11 and encapsulated with a potent radio-sensitizer 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one (NU7441) to allow prostate cancer-specific targeting and sustained delivery over 3 weeks. Preliminary characterization studies showed that the R11-conjugated NPs (R11-NU7441 NPs) had an average size of about 274 ± 80 nm and were stable for up to 5 days in deionized water and serum. The NPs were cytocompatible with immortalized prostate cells (PZ-HPV-7). Further, the particles showed a bi-phasic release of encapsulated NU7441 and were taken up by PC3 prostate cancer cells in a dose- and magnetic field-dependent manner while not being taken up in nonprostate cancer cell lines. In addition, R11-NU7441 NPs were effective radiation sensitizers of prostate cancer cell lines in vitro. These results thus demonstrate the potential of R11-conjugated PLGA NPs as novel platforms for targeted radiosensitization of prostate cancer cells.

Original languageEnglish (US)
Pages (from-to)1632-1639
Number of pages8
JournalJournal of Biomedical Materials Research - Part A
Volume103
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

Cells
Nanoparticles
Cell-Penetrating Peptides
Radiation-Sensitizing Agents
Radiation
Acids
Deionized water
Peptides
8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one
Tissue
Magnetic fields
Pharmaceutical Preparations
polylactic acid-polyglycolic acid copolymer
Milk

Keywords

  • nanoparticles
  • NU7441
  • prostate cancer
  • radiosensitization
  • targeting

ASJC Scopus subject areas

  • Biomedical Engineering
  • Biomaterials
  • Ceramics and Composites
  • Metals and Alloys

Cite this

Polymeric nanoparticles for targeted radiosensitization of prostate cancer cells. / Menon, Jyothi U.; Tumati, Vasu; Hsieh, Jer Tsong; Nguyen, Kytai T.; Saha, Debabrata.

In: Journal of Biomedical Materials Research - Part A, Vol. 103, No. 5, 01.05.2015, p. 1632-1639.

Research output: Contribution to journalArticle

@article{c6ce3d5b0a94447193625d6b6dc34209,
title = "Polymeric nanoparticles for targeted radiosensitization of prostate cancer cells",
abstract = "One of the many issues of using radiosensitizers in a clinical setting is timing daily radiation treatments to coincide with peak drug concentration in target tissue. To overcome this deficit, we have synthesized a novel nanoparticle (NP) system consisting of poly (lactic-co-glycolic acid) (PLGA) NPs conjugated with prostate cancer cell penetrating peptide-R11 and encapsulated with a potent radio-sensitizer 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one (NU7441) to allow prostate cancer-specific targeting and sustained delivery over 3 weeks. Preliminary characterization studies showed that the R11-conjugated NPs (R11-NU7441 NPs) had an average size of about 274 ± 80 nm and were stable for up to 5 days in deionized water and serum. The NPs were cytocompatible with immortalized prostate cells (PZ-HPV-7). Further, the particles showed a bi-phasic release of encapsulated NU7441 and were taken up by PC3 prostate cancer cells in a dose- and magnetic field-dependent manner while not being taken up in nonprostate cancer cell lines. In addition, R11-NU7441 NPs were effective radiation sensitizers of prostate cancer cell lines in vitro. These results thus demonstrate the potential of R11-conjugated PLGA NPs as novel platforms for targeted radiosensitization of prostate cancer cells.",
keywords = "nanoparticles, NU7441, prostate cancer, radiosensitization, targeting",
author = "Menon, {Jyothi U.} and Vasu Tumati and Hsieh, {Jer Tsong} and Nguyen, {Kytai T.} and Debabrata Saha",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/jbm.a.35300",
language = "English (US)",
volume = "103",
pages = "1632--1639",
journal = "Journal of Biomedical Materials Research - Part A",
issn = "0021-9304",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - Polymeric nanoparticles for targeted radiosensitization of prostate cancer cells

AU - Menon, Jyothi U.

AU - Tumati, Vasu

AU - Hsieh, Jer Tsong

AU - Nguyen, Kytai T.

AU - Saha, Debabrata

PY - 2015/5/1

Y1 - 2015/5/1

N2 - One of the many issues of using radiosensitizers in a clinical setting is timing daily radiation treatments to coincide with peak drug concentration in target tissue. To overcome this deficit, we have synthesized a novel nanoparticle (NP) system consisting of poly (lactic-co-glycolic acid) (PLGA) NPs conjugated with prostate cancer cell penetrating peptide-R11 and encapsulated with a potent radio-sensitizer 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one (NU7441) to allow prostate cancer-specific targeting and sustained delivery over 3 weeks. Preliminary characterization studies showed that the R11-conjugated NPs (R11-NU7441 NPs) had an average size of about 274 ± 80 nm and were stable for up to 5 days in deionized water and serum. The NPs were cytocompatible with immortalized prostate cells (PZ-HPV-7). Further, the particles showed a bi-phasic release of encapsulated NU7441 and were taken up by PC3 prostate cancer cells in a dose- and magnetic field-dependent manner while not being taken up in nonprostate cancer cell lines. In addition, R11-NU7441 NPs were effective radiation sensitizers of prostate cancer cell lines in vitro. These results thus demonstrate the potential of R11-conjugated PLGA NPs as novel platforms for targeted radiosensitization of prostate cancer cells.

AB - One of the many issues of using radiosensitizers in a clinical setting is timing daily radiation treatments to coincide with peak drug concentration in target tissue. To overcome this deficit, we have synthesized a novel nanoparticle (NP) system consisting of poly (lactic-co-glycolic acid) (PLGA) NPs conjugated with prostate cancer cell penetrating peptide-R11 and encapsulated with a potent radio-sensitizer 8-dibenzothiophen-4-yl-2-morpholin-4-yl-chromen-4-one (NU7441) to allow prostate cancer-specific targeting and sustained delivery over 3 weeks. Preliminary characterization studies showed that the R11-conjugated NPs (R11-NU7441 NPs) had an average size of about 274 ± 80 nm and were stable for up to 5 days in deionized water and serum. The NPs were cytocompatible with immortalized prostate cells (PZ-HPV-7). Further, the particles showed a bi-phasic release of encapsulated NU7441 and were taken up by PC3 prostate cancer cells in a dose- and magnetic field-dependent manner while not being taken up in nonprostate cancer cell lines. In addition, R11-NU7441 NPs were effective radiation sensitizers of prostate cancer cell lines in vitro. These results thus demonstrate the potential of R11-conjugated PLGA NPs as novel platforms for targeted radiosensitization of prostate cancer cells.

KW - nanoparticles

KW - NU7441

KW - prostate cancer

KW - radiosensitization

KW - targeting

UR - http://www.scopus.com/inward/record.url?scp=84925637916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925637916&partnerID=8YFLogxK

U2 - 10.1002/jbm.a.35300

DO - 10.1002/jbm.a.35300

M3 - Article

C2 - 25088162

AN - SCOPUS:84925637916

VL - 103

SP - 1632

EP - 1639

JO - Journal of Biomedical Materials Research - Part A

JF - Journal of Biomedical Materials Research - Part A

SN - 0021-9304

IS - 5

ER -